-
公开(公告)号：US09222110B2
公开(公告)日：2015-12-29
申请号：US14109587
申请日：2013-12-17
Applicant: South Dakota Board of Regents
CPC classification number: C12P7/56 , C12N9/0006 , C12R1/46 , C12Y101/01027
Abstract: The present invention relates generally to compositions and methods for producing lactic acid using a lactic acid producing microorganism. More specifically, the present invention relates to methods for producing lactic acid with high yield, high concentration and high volumetric productivity through biological fermentation by Enterococcus faecalis, or recombinant microorganisms transformed to produce lactate dehydrogenase using the lactate dehydrogenase-encoding genes derived from E. faecalis.
Abstract translation: 本发明一般涉及使用产生乳酸的微生物生产乳酸的组合物和方法。 更具体地，本发明涉及通过粪肠球菌的生物发酵或转化生产乳酸脱氢酶的重组微生物，使用来源于粪肠球菌的乳酸脱氢酶编码基因来生产具有高产率，高浓度和高体积生产率的乳酸的方法 。
-
42.发明申请COMBINATION USES OF DICHLOROACETATE AND OXAMATE, AND THEIR PRODRUGS, FOR CANCER TREATMENT 有权二氯乙酸酯和氧化镁的组合使用及其制剂用于癌症治疗公开(公告)号：US20150315131A1
公开(公告)日：2015-11-05
申请号：US14699946
申请日：2015-04-29
Applicant: The South Dakota Board of Regents , Sanford Research
Inventor： Xiangming GUAN , Chandrahar DWIVEDI , Yinghong LI , Yang YANG , John H. LEE , Wilson Keith MISKIMINS
IPC: C07C235/74 , A61N5/10 , A61K45/06 , A61K31/225 , A61K31/19
CPC classification number: C07C235/74 , A61K9/0019 , A61K9/008 , A61K9/06 , A61K9/08 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K9/2059 , A61K9/4858 , A61K9/4866 , A61K31/225 , A61K33/24 , A61K45/06 , A61K47/02 , A61K47/10 , A61K47/14 , A61K47/18 , A61K47/26 , A61K47/32 , A61K47/38 , A61K47/44 , A61N5/10 , A61N2005/1098 , C07C233/56 , A61K2300/00
Abstract: The invention novel compounds, pharmaceutical compositions and methods useful for preventing or treating cancer in animals and humans. Also, the invention provides novel prodrugs useful for reducing tumor size, and inhibiting the growth of cancers, inhibiting tumor cell growth and tumor cell proliferation, and promoting apoptosis of tumor cells. When used in combination with chemoradiation thereapy, the novel compounds, compositions and prodrugs provided herein can improve the effectiveness of chemoradiation therapy. The novel compounds, compositions and prodrugs of the invention inhibit PDK and LDH in unique and effective ways.
Abstract translation: 本发明的新颖化合物，药物组合物和可用于预防或治疗动物和人类癌症的方法。 此外，本发明提供了可用于减少肿瘤大小，抑制癌细胞生长，抑制肿瘤细胞生长和肿瘤细胞增殖以及促进肿瘤细胞凋亡的新型前体药物。 当与化学放射疗法组合使用时，本文提供的新型化合物，组合物和前药可以提高放化疗方案的有效性。 本发明的新颖化合物，组合物和前药以独特和有效的方式抑制PDK和LDH。
-
公开(公告)号：US20150190495A1
公开(公告)日：2015-07-09
申请号：US14413385
申请日：2013-07-18
Applicant: SOUTH DAKOTA BOARD OF REGENTS , CAMBRIDGE ENTERPRISE , ACADEMISCH ZIEKENHUIS LEIDEN , UNIVERSITY COLLEGE CORK
Inventor： Ying Fang , Eric John Snijder , Andrew E. Firth , John F. Atkins , Emma Elisabeth Treffers , Ali Tas , Yanhua Li
CPC classification number: A61K39/12 , A61K2039/5254 , A61K2039/552 , C07K14/005 , C07K16/10 , C12N7/00 , C12N2770/10011 , C12N2770/10022 , C12N2770/10034 , C12N2770/10062 , G06F19/18
Abstract: The invention provides the discovery and characterization of a novel arterivirus protein (nsp2TF), whose expression is dependent on −2 ribosomal frameshifting at a site located in the nsp2 coding region. The coding region for the unique TF domain of nsp2TF overlaps the part of ORF1a that encodes the transmembrane region of nsp2 in arteriviruses, including PRRSV, LDV and SHFV. Mutations affecting the expression of nsp2TF impair PRRSV replication and result in a smaller plaque phenotype. Provided herein are arteriviruses that display reduced translation of nsp2TF and/or altered translation of one or more downstream products, arteriviruses in which nsp2TF function is reduced and/or absent, and vaccines comprising said arteriviruses. Also provided herein are diagnostic methods, methods for identifying compounds that inhibit −2 frameshifting, and gene expression tools for eukaryotic systems utilizing −2 frameshifting.
Abstract translation: 本发明提供了新型动脉病毒蛋白（nsp2TF）的发现和表征，其表达依赖于位于nsp2编码区的位点的-2核糖体移码。 nsp2TF的独特的TF结构域的编码区域与动物病毒中nsp2跨膜区的ORF1a部分重叠，包括PRRSV，LDV和SHFV。 影响nsp2TF表达的突变影响PRRSV复制，并导致较小的斑块表型。 本文提供了显示nsp2TF的翻译减少和/或改变的一种或多种下游产物，其中nsp2TF功能减少和/或不存在的动脉病毒以及包含所述动脉病毒的疫苗的翻译的动脉病毒。 本文还提供诊断方法，用于鉴定抑制-2移码的化合物的方法，以及利用-2移码的真核系统的基因表达工具。
-
44.发明申请Rapid and Inexpensive Assay for Evaluation of Antibody Efficacy with Custom-Designed Fluorescent Nanoparticles 审中-公开用定制设计的荧光纳米颗粒评估抗体效力的快速和便宜的测定公开(公告)号：US20140287438A1
公开(公告)日：2014-09-25
申请号：US14214750
申请日：2014-03-15
Applicant: South Dakota Board of Regents
Inventor： Victor Huber , Grigoriy Sereda , James Dale
IPC: G01N33/569
CPC classification number: G01N33/56972 , G01N33/6857
Abstract: A method for determining the efficacy of a vaccine comprising: providing serum from an animal inoculated with a vaccine; providing a plurality of antigen-linked nanoparticles; contacting the serum with the plurality of antigen linked nanoparticles; contacting the serum and the plurality of antigen linked nanoparticles with a plurality of Fc receptor-expressing cells; measuring amount antigen-linked nanoparticle uptake by of the Fc receptor-expressing cells; determining efficacy of the vaccine by comparing the level of antigen-linked nanoparticle uptake to a baseline level of uptake wherein a greater nanoparticle uptake compared to the baseline level of uptake is indicative of greater vaccine efficacy.
Abstract translation: 一种用于确定疫苗功效的方法，包括：从接种疫苗的动物提供血清; 提供多个抗原连接的纳米颗粒; 使血清与多个抗原连接的纳米颗粒接触; 使血清和多个抗原连接的纳米颗粒与多个表达Fc受体的细胞接触; 通过表达Fc受体的细胞测量抗原连接的纳米颗粒的摄取量; 通过将抗原连接的纳米颗粒摄取水平与基线吸收水平进行比较来确定疫苗的功效，其中与基线吸收水平相比，更大的纳米颗粒吸收指示更大的疫苗功效。
-
公开(公告)号：US20140170719A1
公开(公告)日：2014-06-19
申请号：US14109587
申请日：2013-12-17
Applicant: South Dakota Board of Regents
IPC: C12P7/56
CPC classification number: C12P7/56 , C12N9/0006 , C12R1/46 , C12Y101/01027
Abstract: The present invention relates generally to compositions and methods for producing lactic acid using a lactic acid producing microorganism. More specifically, the present invention relates to methods for producing lactic acid with high yield, high concentration and high volumetric productivity through biological fermentation by Enterococcus faecalis, or recombinant microorganisms transformed to produce lactate dehydrogenase using the lactate dehydrogenase-encoding genes derived from E. faecalis.
Abstract translation: 本发明一般涉及使用产生乳酸的微生物生产乳酸的组合物和方法。 更具体地，本发明涉及通过粪肠球菌的生物发酵或转化生产乳酸脱氢酶的重组微生物，使用来源于粪肠球菌的乳酸脱氢酶编码基因来生产具有高产率，高浓度和高体积生产率的乳酸的方法 。
-
Patent Agency Ranking
公开(公告)号：US20250127693A1
公开(公告)日：2025-04-24
申请号：US18919734
申请日：2024-10-18
Applicant: South Dakota Board of Regents
Inventor： Grigoriy Sereda
Abstract: Disclosed herein are dentifrices with low pH-triggered release of pharmacons and other materials to more effectively adhere to the tooth and associated surfaces. The various compositions and methods include novel dental compositions that release materials such as fluoride ions, eugenol, pharmacons or other medicinal payloads under physiologically low pH to extend the material lifespan on the teeth and gums of the user.
-
公开(公告)号：US20250049885A1
公开(公告)日：2025-02-13
申请号：US18782811
申请日：2024-07-24
Applicant: SOUTH DAKOTA BOARD OF REGENTS
Inventor： TUGBA OZDEMIR , BETH BLAKE
Abstract: Articles, such as implants and medical devices, treated with a hyaluronic acid binding peptide are provided. Articles are coated with a surface functionalizing agent which bind to and immobilize the hyaluronic acid binding peptide. Methods of improving and/or reducing foreign body reaction to an article are also provided, as are methods of decreasing inflammation, promoting wound healing, and treating dermal conditions.
-
48.发明申请公开(公告)号：US20240425186A1
公开(公告)日：2024-12-26
申请号：US18828464
申请日：2024-09-09
Applicant: SOUTH DAKOTA BOARD OF REGENTS
Inventor： Haiping Hong , Christian Widener , Gregory Lee Christensen
IPC: B64D31/06 , B64D31/04 , B64D31/08 , B64D43/00 , C08K3/04 , C08K3/38 , C09D5/24 , C09D7/61 , C09D133/02 , C09D163/00 , C09D175/04 , G05D1/652
Abstract: Disclosed herein is a conductive coating composition that includes a functionalized carbon nanomaterial and/or boron nanomaterial and a fluid component. The nanomaterial and fluid component forms hydrogen bond network in the disclosed composition. Because of the formed hydrogen bonds, the disclosed coating exhibits enhanced thermal or electrical conductivity. Also disclosed is a method to improve thermal or electrical conductivity of an existing coating composition.
-
公开(公告)号：US11955626B2
公开(公告)日：2024-04-09
申请号：US17404796
申请日：2021-08-17
Applicant: South Dakota Board of Regents
Inventor： Alevtina Smirnova , Abu Md Numan-Al-Mobin
IPC: H01M4/00 , H01M4/136 , H01M4/36 , H01M4/58 , H01M4/62 , H01M10/052 , H01M10/0525 , H01M10/0562 , H01M4/02
CPC classification number: H01M4/366 , H01M4/136 , H01M4/5825 , H01M4/625 , H01M10/052 , H01M10/0525 , H01M10/0562 , H01M2004/028 , H01M2300/008
Abstract: The present disclosure relates to mixed ionically and electronically conducting solid-state phases for their application in electrochemical devices, such as lithium-metal or lithium ion batteries. The solid-state mixed phase comprises of active cathode and carbon-based structures functionalized by a heteropolyacid (HPA) or a metal salt of a heteropolyacid (Me-HPA) to form a solid-state architecture with incorporated ceramic or glass-ceramic electrolyte for enhanced ionic and electronic conductivity pathways. Combining the solid-state phase components in melted solid-state electrolyte results in perfect distribution, improved adhesion between particles, and improved characteristics of the electrochemical device, such as high charge rates, long-term performance, and broad voltage window.
-
公开(公告)号：US20240043779A1
公开(公告)日：2024-02-08
申请号：US18487600
申请日：2023-10-16
Applicant: SOUTH DAKOTA BOARD OF REGENTS
Inventor： SCOTT WOOD , RAM SARASWAT
CPC classification number: C12M23/16 , B01L3/502715 , C12M23/22 , C12M25/14
Abstract: A platform for culturing modular, biomimetic compositions such as tissues, cartilage, bone, synovial membrane, is accomplished through the use of a 3D printed platform with cell well, well plate frame with culture and analysis modules, coverglass bottoms for imaging, and cross-talk flow to connect tissue modules for paracrine signaling. Human chondrocytes can be generated and kept in a cell back and expanded to zonal models, osteoarthritis progression models. The use of titanium oxide nanotubes and can produce bone marrow stem cells differentiated toward osteoblasts. The synovial membrane can be modeled by an electrospun mesh, macrophages with an inducible phenotype (quiescent vs. wound repair vs. inflammatory).
-
-
-
-
-
-
-
-
-
Search Results
197
records
(took 0.034 seconds)
